RU2020139190A - Доставка биомолекул в клетки иммунной системы - Google Patents
Доставка биомолекул в клетки иммунной системы Download PDFInfo
- Publication number
- RU2020139190A RU2020139190A RU2020139190A RU2020139190A RU2020139190A RU 2020139190 A RU2020139190 A RU 2020139190A RU 2020139190 A RU2020139190 A RU 2020139190A RU 2020139190 A RU2020139190 A RU 2020139190A RU 2020139190 A RU2020139190 A RU 2020139190A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- immune system
- antigen
- paragraphs
- compound
- Prior art date
Links
- 210000000987 immune system Anatomy 0.000 title claims 66
- 238000000034 method Methods 0.000 claims 115
- 210000004027 cell Anatomy 0.000 claims 84
- 239000000427 antigen Substances 0.000 claims 59
- 108091007433 antigens Proteins 0.000 claims 59
- 102000036639 antigens Human genes 0.000 claims 59
- 150000001875 compounds Chemical class 0.000 claims 43
- 210000001744 T-lymphocyte Anatomy 0.000 claims 29
- 239000006285 cell suspension Substances 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 8
- 210000000172 cytosol Anatomy 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 5
- 239000002671 adjuvant Substances 0.000 claims 5
- 230000003614 tolerogenic effect Effects 0.000 claims 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 210000002540 macrophage Anatomy 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108010051219 Cre recombinase Proteins 0.000 claims 3
- 108020005198 Long Noncoding RNA Proteins 0.000 claims 3
- 108091029810 SaRNA Proteins 0.000 claims 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 230000005867 T cell response Effects 0.000 claims 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 3
- 102000040945 Transcription factor Human genes 0.000 claims 3
- 108091023040 Transcription factor Proteins 0.000 claims 3
- 108020004566 Transfer RNA Proteins 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 210000003714 granulocyte Anatomy 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 108091070501 miRNA Proteins 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 210000001616 monocyte Anatomy 0.000 claims 3
- 210000000822 natural killer cell Anatomy 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 229940044601 receptor agonist Drugs 0.000 claims 3
- 239000000018 receptor agonist Substances 0.000 claims 3
- 229940078677 sarna Drugs 0.000 claims 3
- 239000004055 small Interfering RNA Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000287828 Gallus gallus Species 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000244206 Nematoda Species 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 230000016788 immune system process Effects 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108090000342 C-Type Lectins Proteins 0.000 claims 1
- 102000003930 C-Type Lectins Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 102000012064 NLR Proteins Human genes 0.000 claims 1
- 108091005686 NOD-like receptors Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108091005685 RIG-I-like receptors Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 238000010924 continuous production Methods 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000004964 innate lymphoid cell Anatomy 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Sustainable Development (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Clinical Laboratory Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Mechanical Engineering (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073548P | 2014-10-31 | 2014-10-31 | |
| US62/073,548 | 2014-10-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017118935A Division RU2739794C2 (ru) | 2014-10-31 | 2015-10-30 | Доставка биомолекул в клетки иммунной системы |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020139190A true RU2020139190A (ru) | 2021-01-26 |
Family
ID=55858434
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020139190A RU2020139190A (ru) | 2014-10-31 | 2015-10-30 | Доставка биомолекул в клетки иммунной системы |
| RU2017118935A RU2739794C2 (ru) | 2014-10-31 | 2015-10-30 | Доставка биомолекул в клетки иммунной системы |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017118935A RU2739794C2 (ru) | 2014-10-31 | 2015-10-30 | Доставка биомолекул в клетки иммунной системы |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11111472B2 (enExample) |
| EP (1) | EP3212772A4 (enExample) |
| JP (2) | JP7523203B2 (enExample) |
| KR (2) | KR102819064B1 (enExample) |
| CN (2) | CN122564053A (enExample) |
| AU (2) | AU2015338893A1 (enExample) |
| BR (1) | BR112017009050A2 (enExample) |
| CA (1) | CA2964392A1 (enExample) |
| IL (1) | IL252005B (enExample) |
| RU (2) | RU2020139190A (enExample) |
| SG (2) | SG11201703044PA (enExample) |
| WO (1) | WO2016070136A1 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1907000T4 (da) * | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US10124336B2 (en) | 2013-08-16 | 2018-11-13 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| CN122564053A (zh) | 2014-10-31 | 2026-08-14 | 麻省理工学院 | 递送生物分子至免疫细胞 |
| WO2016077761A1 (en) | 2014-11-14 | 2016-05-19 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
| AU2016206870B2 (en) | 2015-01-12 | 2022-02-17 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| WO2016168680A1 (en) * | 2015-04-17 | 2016-10-20 | Exocyte Therapeutics Pte Ltd. | Method for developing exosome-based vaccines |
| US20180066223A1 (en) | 2015-04-17 | 2018-03-08 | Xcell Biosciences, Inc. | Cancer cell enrichment system |
| JP6925984B2 (ja) | 2015-07-09 | 2021-08-25 | マサチューセッツ インスティテュート オブ テクノロジー | 無核細胞への物質の送達 |
| CN108350419A (zh) * | 2015-07-20 | 2018-07-31 | 安吉克莱茵生物科学有限公司 | 干细胞移植方法和干细胞移植组合物 |
| US11613759B2 (en) | 2015-09-04 | 2023-03-28 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| EP3402890B1 (en) * | 2016-01-12 | 2025-01-01 | SQZ Biotechnologies Company | Intracellular delivery of complexes |
| EP3429618B1 (en) | 2016-03-16 | 2024-02-21 | Amal Therapeutics SA | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| JP2019518009A (ja) * | 2016-05-03 | 2019-06-27 | スクイーズ バイオテクノロジーズ カンパニー | 寛容性を誘導するための生体分子の細胞内送達 |
| CN109415741A (zh) | 2016-05-03 | 2019-03-01 | Sqz生物技术公司 | 细胞内递送生物分子以诱导耐受性 |
| WO2017203362A1 (en) * | 2016-05-25 | 2017-11-30 | The Council Of The Queensland Institute Of Medical Research | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |
| CA3026182A1 (en) | 2016-06-03 | 2017-12-07 | Steven Greenberg | Klrg1 signaling therapy |
| CN106047818A (zh) * | 2016-08-05 | 2016-10-26 | 武汉赛云博生物科技有限公司 | 癌胚抗原特异性tcr基因修饰的t细胞及其抑癌用途 |
| KR20190057345A (ko) * | 2016-09-21 | 2019-05-28 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| WO2018064387A1 (en) * | 2016-09-28 | 2018-04-05 | Novartis Ag | Porous membrane-based macromolecule delivery system |
| WO2018074980A1 (en) * | 2016-10-21 | 2018-04-26 | Agency For Science, Technology And Research | Device, system and method for intracellular delivery of substances |
| WO2018089497A1 (en) | 2016-11-08 | 2018-05-17 | Georgia Tech Research Corporation | Methods for convectively-driven intracellular delivery |
| ES2924063T3 (es) | 2016-12-22 | 2022-10-04 | Avectas Ltd | Liberación intracelular sin vector mediante permeabilización reversible |
| CA3052463A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| WO2019018497A1 (en) * | 2017-07-18 | 2019-01-24 | President And Fellows Of Harvard College | INTRACELLULAR DELIVERY USING MICROFLUIDIC ASSISTED CELLULAR SCREENING (MACS) |
| WO2019037055A1 (zh) * | 2017-08-24 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 人 GRD4 基因的 shRNA 及其应用 |
| EP3704257A4 (en) * | 2017-11-02 | 2021-08-25 | Indee. Pty. Ltd. | INTRACELLULAR ADMINISTRATION AND RELATED PROCESS |
| US20210317187A1 (en) * | 2017-12-05 | 2021-10-14 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to modulate antibody production |
| US11365390B2 (en) | 2017-12-19 | 2022-06-21 | Xcell Biosciences, Inc. | Methods of modulating cell phenotype by way of regulating the gaseous environment |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| BR112020018612A2 (pt) * | 2018-03-12 | 2020-12-29 | Sqz Biotechnologies Company | Entrega intracelular de biomoléculas para modificar a resposta imune |
| MA52003A (fr) | 2018-03-12 | 2021-01-20 | Sqz Biotechnologies Co | Procédés de traitement de maladies associées au hpv |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CN113165866A (zh) * | 2018-10-04 | 2021-07-23 | Sqz生物技术公司 | 细胞内递送生物分子以增强抗原呈递细胞功能 |
| CN112840015A (zh) * | 2018-11-12 | 2021-05-25 | 飞秒生物医学有限公司 | 控制细胞内递送物质的方法及装置 |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2020154696A1 (en) | 2019-01-25 | 2020-07-30 | Sqz Biotechnologies Company | Anucleate cell-derived vaccines |
| WO2020172198A1 (en) * | 2019-02-18 | 2020-08-27 | Duke University | Prr-activating and microrna-inhibiting molecules and methods of using same |
| BR112021016903A2 (pt) * | 2019-02-28 | 2021-11-03 | Sqz Biotechnologies Co | Administração de biomoléculas a pbmcs para modificação de uma resposta imune |
| DK3934673T3 (da) * | 2019-03-08 | 2026-04-07 | Massachusetts Inst Technology | Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi |
| JP7353381B2 (ja) * | 2019-03-12 | 2023-09-29 | エムエックスティー バイオテック | 細胞内物質伝達のためのマイクロ流体システムおよび方法 |
| CN113613663B (zh) * | 2019-03-29 | 2024-09-03 | 雀巢产品有限公司 | 用于增加t细胞功能的组合物和方法 |
| WO2020210162A1 (en) | 2019-04-08 | 2020-10-15 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
| WO2020207456A1 (en) * | 2019-04-11 | 2020-10-15 | The Chinese University Of Hong Kong | Systems and methods for controlled membrane disruption |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| US11685891B2 (en) | 2019-05-17 | 2023-06-27 | Regents Of The University Of Colorado | Precise mechanical disruption for intracellular delivery to cells and small organisms |
| WO2020252215A1 (en) | 2019-06-12 | 2020-12-17 | Cellfe, Inc. | Methods and systems for cell labeling and imaging |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| EP4118219A4 (en) * | 2020-03-11 | 2024-04-17 | Shanghai Belief-Delivery Biomed Co., Ltd. | Novel use of aspirin compound in increasing nucleic acid expression |
| EP3892720A1 (en) | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US20230181712A1 (en) | 2020-05-11 | 2023-06-15 | Hoffmann-La Roche Inc. | Combination therapy with modified pbmcs and an immunoconjugate |
| KR102654518B1 (ko) * | 2020-05-26 | 2024-04-04 | 가톨릭대학교 산학협력단 | Lsp1 결핍 t 세포 |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| US20230227790A1 (en) * | 2020-06-09 | 2023-07-20 | Scot R. Shepard | Method of assemblying two-component virus-like particle |
| WO2022026621A1 (en) | 2020-07-29 | 2022-02-03 | Sqz Biotechnologies Company | Methods to stimulate immune responses to mutant ras using anucleate cells |
| KR20230058389A (ko) | 2020-07-29 | 2023-05-03 | 에스큐지 바이오테크놀로지스 컴퍼니 | 유핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법 |
| JP2023539370A (ja) * | 2020-09-02 | 2023-09-13 | スクイーズ バイオテクノロジーズ カンパニー | 有核細胞を使用してタンパク質に対するｈｌａ非依存的な免疫応答を刺激する方法 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| IL302976A (en) | 2020-11-18 | 2023-07-01 | Cellfe Inc | Mechanoporation-based methods and systems for high-throughput charge transfer into biological cells |
| US12227729B2 (en) | 2020-12-24 | 2025-02-18 | Cellfe, Inc. | Methods and systems for high-throughput cell processing |
| US20220296691A1 (en) | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
| US12150982B2 (en) | 2020-12-29 | 2024-11-26 | Stemcell Technologies Canada Inc. | Formulations of PBMCs |
| JP2024503278A (ja) | 2020-12-29 | 2024-01-25 | スクイーズ バイオテクノロジーズ カンパニー | 修飾ｐｂｍｃを用いたがんの治療方法 |
| JP2024503277A (ja) | 2020-12-29 | 2024-01-25 | スクイーズ バイオテクノロジーズ カンパニー | 活性化抗原担体の製剤 |
| CN116670265B (zh) | 2020-12-29 | 2026-08-04 | 加拿大干细胞技术公司 | 用于扰动细胞膜的具有并行缩窄部的高通量微流控芯片 |
| EP4277981A1 (en) * | 2021-01-13 | 2023-11-22 | The General Hospital Corporation | Viscoelastic mechanoporation systems and methods of use thereof |
| US20240139739A1 (en) * | 2021-02-26 | 2024-05-02 | Hewlett-Packard Development Company, L.P. | A microfluidic channel including a fluidic pump to direct a cell through a constriction region |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| US20240173717A1 (en) * | 2021-04-01 | 2024-05-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Multistage device and method for intracellular delivery |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| US20250327027A1 (en) | 2021-07-29 | 2025-10-23 | Stemcell Technologies Canada Inc. | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| WO2023034941A1 (en) * | 2021-09-01 | 2023-03-09 | VisiCELL Medical Inc. | Microsphere facilitated intracellular delivery and associated methods and devices |
| CN113862112B (zh) * | 2021-09-03 | 2023-08-15 | 南昌大学 | 微流控离心式挤压的细胞转染系统及细胞转染方法 |
| EP4426828A1 (en) | 2021-11-01 | 2024-09-11 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
| CN118510888A (zh) | 2021-11-11 | 2024-08-16 | 加拿大干细胞技术公司 | 通过微流体递送来产生增强的肿瘤浸润性淋巴细胞的方法 |
| US20250057980A1 (en) | 2021-12-22 | 2025-02-20 | Tome Biosciences, Inc. | Co-Delivery of a Gene Editor Construct and a Donor Template |
| WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| EP4561620A1 (en) | 2022-07-28 | 2025-06-04 | Stemcell Technologies Canada Inc. | Methods for treating cancer with enhanced antigen presenting cells |
| JP2025527190A (ja) | 2022-07-28 | 2025-08-20 | ステムセル テクノロジーズ カナダ インコーポレイテッド | 強化抗原提示細胞製剤 |
| WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
| WO2024233781A1 (en) * | 2023-05-10 | 2024-11-14 | Sigyn Therapeutics, Inc. | Devices for enhancing the activity of therapeutic antibodies |
| WO2024234006A1 (en) | 2023-05-11 | 2024-11-14 | Tome Biosciences, Inc. | Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs) |
| WO2025050069A1 (en) | 2023-09-01 | 2025-03-06 | Tome Biosciences, Inc. | Programmable gene insertion using engineered integration enzymes |
| WO2025224107A1 (en) | 2024-04-22 | 2025-10-30 | Basecamp Research Ltd | Method and compositions for detecting off-target editing |
| WO2025224182A2 (en) | 2024-04-23 | 2025-10-30 | Basecamp Research Ltd | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2502621C3 (de) | 1975-01-23 | 1978-09-14 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Messung elastischer und dielektrischer Eigenschaften der Membran lebender Zellen |
| US4376634A (en) | 1980-05-30 | 1983-03-15 | Mallinckrodt, Inc. | Assay kit having syringe, dilution device and reagents within sealed container |
| US4478824A (en) | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
| FR2569477B1 (fr) | 1984-08-24 | 1987-01-02 | Descartes Universite Rene | Appareil et procede pour la determination de la deformabilite des globules rouges du sang |
| JP2720161B2 (ja) | 1988-02-01 | 1998-02-25 | 株式会社アドバンス | 細胞変形能測定装置 |
| JP2685544B2 (ja) | 1988-11-11 | 1997-12-03 | 株式会社日立製作所 | 血液フィルタおよび血液検査方法並びに血液検査装置 |
| JP2532707B2 (ja) | 1990-03-08 | 1996-09-11 | 佑二 菊池 | 血液回路及びこれを用いた血液測定装置及び血液測定方法 |
| ATE162402T1 (de) | 1990-04-24 | 1998-02-15 | Flustat Pty Ltd | Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff |
| US5658892A (en) | 1993-01-15 | 1997-08-19 | The General Hospital Corporation | Compound delivery using high-pressure impulse transients |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| WO1996027392A1 (en) | 1995-03-08 | 1996-09-12 | The Scripps Research Institute | Antigen presenting system and methods for activation of t-cells |
| US6051409A (en) | 1995-09-25 | 2000-04-18 | Novartis Finance Corporation | Method for achieving integration of exogenous DNA delivered by non-biological means to plant cells |
| US6133503A (en) | 1995-10-31 | 2000-10-17 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
| EP0874635B1 (en) | 1995-12-04 | 2003-03-19 | Puget Sound Blood Center | Nonimmunogenic platelet and red blood cell compositions |
| AU734196B2 (en) | 1996-03-28 | 2001-06-07 | Whitehead Institute | Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
| US5885470A (en) | 1997-04-14 | 1999-03-23 | Caliper Technologies Corporation | Controlled fluid transport in microfabricated polymeric substrates |
| EP0882448B1 (en) | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
| SE9704076D0 (sv) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
| GB9816583D0 (en) | 1998-07-31 | 1998-09-30 | Univ Ulster | Nucleic acid carrier |
| AU5757100A (en) | 1999-06-21 | 2001-01-09 | General Hospital Corporation, The | Methods and devices for cell culturing and organ assist systems |
| JP2002325572A (ja) | 2000-12-25 | 2002-11-12 | Univ Osaka | 外来物質の導入方法 |
| AU2002252073A1 (en) | 2001-02-22 | 2002-09-12 | The Scepens Eye Research Institute, Inc. | Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions |
| WO2003020039A1 (en) | 2001-08-28 | 2003-03-13 | Rush-Presbyterian-St. Luke's Medical Center | Immune tolerance to predetermined antigens |
| AU2002353741A1 (en) | 2001-11-27 | 2003-06-10 | Cellectricon Ab | A method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| US20030133922A1 (en) | 2002-01-15 | 2003-07-17 | Kasha John R. | Oral tolerance using allogeneic platelets in ITP |
| US7148059B1 (en) | 2002-02-22 | 2006-12-12 | Ionoptix Corporation | Myocyte culture pacing apparatus |
| WO2003104788A1 (ja) | 2002-06-05 | 2003-12-18 | 松下電器産業株式会社 | 細胞外電位測定デバイスおよびその製造方法 |
| GB0214528D0 (en) | 2002-06-24 | 2002-08-07 | Univ Aberdeen | Materials and methods for induction of immune tolerance |
| GB0224442D0 (en) * | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| CA2513072A1 (en) | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| US20060134067A1 (en) | 2003-02-18 | 2006-06-22 | Maxcyte, Inc. | Loading of cells with antigens by electroporation |
| EP1780266A4 (en) | 2004-06-17 | 2009-09-09 | Ken Nakata | CELL CULTIVATION PROCESS WITH BIOMECHANICAL LOAD TREATMENT AND ITS DEVICE |
| CN1981073B (zh) | 2004-07-27 | 2011-07-13 | 帝斯曼知识产权资产管理有限公司 | 用于制备碳纳米管/超高摩尔质量聚乙烯复合纤维的方法 |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| US20060134772A1 (en) | 2004-11-18 | 2006-06-22 | The Regents Of The University Of California | System for locating cells and for cellular analysis |
| WO2006095330A2 (en) | 2005-03-10 | 2006-09-14 | Yeda Research And Development Co. Ltd. | Methods and immunogenic cell preparations for treating antigen-associated diseases |
| US7704743B2 (en) | 2005-03-30 | 2010-04-27 | Georgia Tech Research Corporation | Electrosonic cell manipulation device and method of use thereof |
| KR100760309B1 (ko) | 2005-07-06 | 2007-10-05 | 한국과학기술원 | 미소필터를 이용한 미소입자 변형성 분석기 |
| US7993821B2 (en) | 2005-08-11 | 2011-08-09 | University Of Washington | Methods and apparatus for the isolation and enrichment of circulating tumor cells |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| WO2007097934A2 (en) | 2006-02-17 | 2007-08-30 | Elusys Therapeutics, Inc. | Methods and compositions for using erythrocytes as carriers for delivery of drugs |
| US8293524B2 (en) | 2006-03-31 | 2012-10-23 | Fluxion Biosciences Inc. | Methods and apparatus for the manipulation of particle suspensions and testing thereof |
| US20070249038A1 (en) | 2006-04-21 | 2007-10-25 | Andrea Adamo | Microfluidic device for single cell targeted operations |
| AU2007284454A1 (en) | 2006-08-17 | 2008-02-21 | Massachusetts Institute Of Technology | Method and apparatus for microfluidic injection |
| US20120264108A1 (en) | 2007-01-05 | 2012-10-18 | The Regents Of The University Of California | Intracellular Molecular Delivery Based On Nanostructure Injectors |
| US20080241844A1 (en) | 2007-02-06 | 2008-10-02 | Network Biosystems, Inc. | Devices and Methods for the Performance of Miniaturized In Vitro Assays |
| US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
| US8841135B2 (en) | 2007-06-20 | 2014-09-23 | University Of Washington | Biochip for high-throughput screening of circulating tumor cells |
| EP2169070B1 (en) | 2007-06-21 | 2015-06-10 | National University Corporation Nagoya University | Method for introducing foreign substance into cell having cell wall |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| GB0718160D0 (en) | 2007-09-18 | 2007-10-24 | Medical Res Council | Methods |
| EP2057998A1 (en) | 2007-10-31 | 2009-05-13 | Universitätsklinikum Hamburg-Eppendorf | Use of modified cells for the treatment of multiple sclerosis |
| KR100891487B1 (ko) | 2007-11-01 | 2009-04-01 | 한국과학기술원 | 미세유체제어기술 기반으로 한 난모세포 또는 난자의 핵제거 시스템 |
| CN101874201B (zh) | 2007-11-28 | 2012-08-15 | 柯尼卡美能达精密光学株式会社 | 血液流动性测量装置及血液流动性测量方法 |
| US20090280518A1 (en) | 2008-05-12 | 2009-11-12 | Massachusetts Institute Of Technology | System for high throughput measurement of mechanical properties of cells |
| JP2010002582A (ja) | 2008-06-19 | 2010-01-07 | Konica Minolta Business Technologies Inc | 画像形成装置 |
| JP5137129B2 (ja) | 2008-07-23 | 2013-02-06 | 国立大学法人山口大学 | 血液細胞の力学的特性測定装置 |
| EP2321405A4 (en) | 2008-08-08 | 2012-09-12 | Agency Science Tech & Res | MICROFLUIDIC CONTINUOUS FLOW DEVICE |
| US8211656B2 (en) | 2008-08-13 | 2012-07-03 | The Invention Science Fund I, Llc | Biological targeting compositions and methods of using the same |
| US8187864B2 (en) | 2008-10-01 | 2012-05-29 | The Governing Council Of The University Of Toronto | Exchangeable sheets pre-loaded with reagent depots for digital microfluidics |
| US20110091973A1 (en) | 2008-12-09 | 2011-04-21 | Glaser Larry F | Modified and fusion enhanced erythrocytes, cells and uses thereof |
| US9157550B2 (en) | 2009-01-05 | 2015-10-13 | The Board Of Trustees Of The University Of Illinois | Microfluidic systems and methods |
| EP2405959A4 (en) | 2009-03-13 | 2013-10-16 | Univ Tufts | METHODS, DEVICES AND KITS FOR INTRODUCING GENETIC MATERIAL IN LIVING CELLS |
| US9017991B2 (en) | 2009-03-13 | 2015-04-28 | Tufts University | Methods tip assemblies and kits for introducing material into cells |
| US20120107925A1 (en) | 2009-03-20 | 2012-05-03 | Mo Huang Li | Devices for separating cells and methods of using them |
| JP4849278B2 (ja) | 2009-03-27 | 2012-01-11 | セイコーエプソン株式会社 | 細胞処理デバイス、細胞処理カートリッジおよび体液処理システム |
| WO2010129671A2 (en) | 2009-05-08 | 2010-11-11 | Chauncey Sayre | Method of and apparatus for changing one type of cell into another type of cell |
| GB0909754D0 (en) | 2009-06-05 | 2009-07-22 | Magnani Mauro | Drug delivery systems |
| EP2449135B1 (en) | 2009-06-30 | 2016-01-06 | Sangamo BioSciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| KR101125060B1 (ko) | 2009-07-22 | 2012-03-21 | 한국과학기술원 | 입자를 포획하는 미세유체 소자 및 이를 이용한 입자 포획 방법 |
| US9364831B2 (en) | 2009-08-08 | 2016-06-14 | The Regents Of The University Of California | Pulsed laser triggered high speed microfluidic switch and applications in fluorescent activated cell sorting |
| ES2600932T3 (es) | 2009-10-27 | 2017-02-13 | Erytech Pharma | Composición para inducir una tolerancia inmunitaria específica |
| US20130023051A1 (en) | 2009-12-21 | 2013-01-24 | Keygene N.V. | Techniques for transfecting protoplasts |
| EP2516320A4 (en) | 2009-12-23 | 2015-03-04 | Cytovera Inc | SYSTEM AND METHOD FOR PARTICLE FILTRATION |
| WO2011084882A2 (en) | 2010-01-05 | 2011-07-14 | Contrafect Corporation | Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria |
| US8844570B2 (en) | 2010-02-01 | 2014-09-30 | California Institute Of Technology | Generating binary states using a microfluidic channel |
| JP5704590B2 (ja) | 2010-02-05 | 2015-04-22 | 国立大学法人東京農工大学 | サイズ選択マイクロキャビティアレイを用いた循環腫瘍細胞の検出 |
| US9458489B2 (en) | 2010-03-04 | 2016-10-04 | Massachusetts Institute Of Technology | Microfluidics sorter for cell detection and isolation |
| US20110289043A1 (en) | 2010-03-22 | 2011-11-24 | Brown University Research Foundation | Computational methods and compositions |
| KR20130100290A (ko) | 2010-08-30 | 2013-09-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법 |
| US10023847B2 (en) | 2010-11-25 | 2018-07-17 | Imnate Sarl | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination |
| CA2825093A1 (en) | 2011-01-19 | 2012-07-26 | The University Of British Columbia | Apparatus and method for particle separation |
| MX363013B (es) | 2011-02-25 | 2019-03-04 | Recombinetics Inc | Animales genéticamente modificados y métodos para su obtención. |
| EP2681306B1 (en) | 2011-02-28 | 2019-01-09 | President and Fellows of Harvard College | Cell culture system |
| CN102250842A (zh) | 2011-05-23 | 2011-11-23 | 昆明理工大学 | 一种电穿孔转染昆虫细胞的方法 |
| CN116179323A (zh) | 2011-05-27 | 2023-05-30 | 不列颠哥伦比亚大学 | 用于高通量分析的微流控细胞捕获和分析设备 |
| HRP20141230T1 (hr) | 2011-07-05 | 2015-02-13 | SOTIO a.s. | Naäśini i postupci aktivne staniäśne imunoterapije raka upotrebom tumorskih stanica usmrä†enih visokim hidrostatskim tlakom, te dendritiäśkih stanica |
| US20130065314A1 (en) | 2011-08-25 | 2013-03-14 | Phytocentric Biotech Inc. | Algal transformation systems, compositions and methods |
| WO2013059343A1 (en) * | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
| CN104684546A (zh) | 2012-06-07 | 2015-06-03 | 哈佛大学校长及研究员协会 | 用于药物靶向的纳米疗法 |
| US9255245B2 (en) | 2012-07-03 | 2016-02-09 | Agilent Technologies, Inc. | Sample probes and methods for sampling intracellular material |
| EP4397759A3 (en) | 2012-10-23 | 2024-10-09 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| CN102925337B (zh) | 2012-11-08 | 2014-06-18 | 武汉友芝友生物制药有限公司 | 一种微流体细胞捕获芯片及其制备方法 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| GB201300049D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-stimulatory dendritic cells |
| GB201300052D0 (en) | 2013-01-03 | 2013-02-20 | Transimmune Ag | Method for obtaining immuno-suppressive dendritic cells |
| WO2014120956A1 (en) | 2013-01-30 | 2014-08-07 | Asta Fluidic Technologies, Inc. | Microfluidic-based fetal red blood cell detection |
| US9725709B2 (en) | 2013-03-12 | 2017-08-08 | OpenCell Technologies, Inc. | Intracellular delivery and transfection methods and devices |
| WO2014151888A1 (en) | 2013-03-15 | 2014-09-25 | The Regents Of The University Of California | High-throughput cargo delivery into live cells using photothermal platforms |
| KR20140115560A (ko) | 2013-03-21 | 2014-10-01 | 인하대학교 산학협력단 | 기계적 스트레스를 이용한 단세포 생물체 개질 방법 및 이에 사용되는 장치 |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| KR101508974B1 (ko) | 2013-05-14 | 2015-04-07 | 한국과학기술연구원 | 종양 세포의 검출장치 및 검출방법 |
| US10124336B2 (en) * | 2013-08-16 | 2018-11-13 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
| CA2927947A1 (en) | 2013-10-22 | 2015-04-30 | Cellanyx Diagnostics, Llc | Systems, devices and methods for microfluidic culturing, manipulation and analysis of tissues and cells |
| US10137673B2 (en) | 2013-12-31 | 2018-11-27 | Canon U.S. Life Sciences, Inc. | Methods and systems for continuous flow cell lysis in a microfluidic device |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| SG11201608701QA (en) | 2014-04-18 | 2016-11-29 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| WO2016003485A1 (en) | 2014-07-03 | 2016-01-07 | Massachusetts Institute Of Technology | Microfluidic assay for rapid optimization of cell electroporation |
| CN122564053A (zh) | 2014-10-31 | 2026-08-14 | 麻省理工学院 | 递送生物分子至免疫细胞 |
| WO2016077761A1 (en) | 2014-11-14 | 2016-05-19 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
| WO2016094715A2 (en) | 2014-12-10 | 2016-06-16 | Berkeley Lights, Inc. | Movement and selection of micro-objects in a microfluidic apparatus |
| EP3242946B1 (en) | 2015-01-07 | 2026-08-19 | Indee. Inc. | A method for mechanical and hydrodynamic microfluidic transfection and apparatus therefor |
| AU2016206870B2 (en) | 2015-01-12 | 2022-02-17 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
| WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
| GB201513278D0 (en) | 2015-07-03 | 2015-09-09 | Transimmune Ag And Yale University | Device and method for obtaining immunostimulatory antigen-presenting cells |
| JP6925984B2 (ja) | 2015-07-09 | 2021-08-25 | マサチューセッツ インスティテュート オブ テクノロジー | 無核細胞への物質の送達 |
| US20190382796A1 (en) | 2015-09-04 | 2019-12-19 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules mediated by a surface with pores |
| US11613759B2 (en) | 2015-09-04 | 2023-03-28 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| AU2016374643B2 (en) | 2015-12-22 | 2023-12-14 | Sangui Bio Pty. Ltd | Therapeutic methods using erythrocytes |
| CN108697733A (zh) | 2016-01-11 | 2018-10-23 | 鲁比厄斯治疗法股份有限公司 | 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法 |
| EP3402890B1 (en) | 2016-01-12 | 2025-01-01 | SQZ Biotechnologies Company | Intracellular delivery of complexes |
| JP2019518009A (ja) | 2016-05-03 | 2019-06-27 | スクイーズ バイオテクノロジーズ カンパニー | 寛容性を誘導するための生体分子の細胞内送達 |
| CN109415741A (zh) | 2016-05-03 | 2019-03-01 | Sqz生物技术公司 | 细胞内递送生物分子以诱导耐受性 |
| US20170326213A1 (en) | 2016-05-16 | 2017-11-16 | Augusta University Research Institute, Inc. | Protein-Coupled Red Blood Cell Compositions and Methods of Their Use |
| CN106244543A (zh) | 2016-07-29 | 2016-12-21 | 北京时合生物科技有限公司 | 一种pbmc体外诱导分化成为树突状细胞的方法 |
| WO2018089497A1 (en) | 2016-11-08 | 2018-05-17 | Georgia Tech Research Corporation | Methods for convectively-driven intracellular delivery |
| WO2020154696A1 (en) | 2019-01-25 | 2020-07-30 | Sqz Biotechnologies Company | Anucleate cell-derived vaccines |
| US20230130686A1 (en) | 2021-10-25 | 2023-04-27 | Massachusetts Institute Of Technology | Devices and systems for delivery of materials to cells |
-
2015
- 2015-10-30 CN CN202610388285.3A patent/CN122564053A/zh active Pending
- 2015-10-30 CA CA2964392A patent/CA2964392A1/en active Pending
- 2015-10-30 CN CN201580062411.6A patent/CN107109362A/zh active Pending
- 2015-10-30 WO PCT/US2015/058489 patent/WO2016070136A1/en not_active Ceased
- 2015-10-30 RU RU2020139190A patent/RU2020139190A/ru unknown
- 2015-10-30 KR KR1020237021840A patent/KR102819064B1/ko active Active
- 2015-10-30 SG SG11201703044PA patent/SG11201703044PA/en unknown
- 2015-10-30 RU RU2017118935A patent/RU2739794C2/ru active
- 2015-10-30 US US15/523,142 patent/US11111472B2/en active Active
- 2015-10-30 KR KR1020177013389A patent/KR20170074235A/ko not_active Ceased
- 2015-10-30 SG SG10201903912XA patent/SG10201903912XA/en unknown
- 2015-10-30 EP EP15855640.7A patent/EP3212772A4/en active Pending
- 2015-10-30 AU AU2015338893A patent/AU2015338893A1/en not_active Abandoned
- 2015-10-30 JP JP2017521144A patent/JP7523203B2/ja active Active
- 2015-10-30 BR BR112017009050A patent/BR112017009050A2/pt not_active Application Discontinuation
-
2017
- 2017-04-27 IL IL252005A patent/IL252005B/en unknown
-
2021
- 2021-08-04 US US17/394,125 patent/US12410392B2/en active Active
- 2021-09-10 JP JP2021147556A patent/JP2021192630A/ja active Pending
-
2022
- 2022-02-23 AU AU2022201222A patent/AU2022201222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102819064B1 (ko) | 2025-06-12 |
| US11111472B2 (en) | 2021-09-07 |
| SG11201703044PA (en) | 2017-05-30 |
| IL252005A0 (en) | 2017-06-29 |
| AU2015338893A1 (en) | 2017-05-04 |
| JP2017533702A (ja) | 2017-11-16 |
| AU2022201222A1 (en) | 2022-03-17 |
| CN122564053A (zh) | 2026-08-14 |
| CN107109362A (zh) | 2017-08-29 |
| AU2022201222B2 (en) | 2024-11-28 |
| RU2739794C2 (ru) | 2020-12-28 |
| JP2021192630A (ja) | 2021-12-23 |
| JP7523203B2 (ja) | 2024-07-26 |
| WO2016070136A1 (en) | 2016-05-06 |
| US20220064584A1 (en) | 2022-03-03 |
| CA2964392A1 (en) | 2016-05-06 |
| RU2017118935A (ru) | 2018-12-03 |
| KR20170074235A (ko) | 2017-06-29 |
| US12410392B2 (en) | 2025-09-09 |
| BR112017009050A2 (pt) | 2018-01-30 |
| KR20230098928A (ko) | 2023-07-04 |
| IL252005B (en) | 2022-04-01 |
| RU2017118935A3 (enExample) | 2019-10-01 |
| EP3212772A4 (en) | 2018-10-03 |
| US20180142198A1 (en) | 2018-05-24 |
| EP3212772A1 (en) | 2017-09-06 |
| SG10201903912XA (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017118935A (ru) | Доставка биомолекул в клетки иммунной системы | |
| JP2017533702A5 (enExample) | ||
| TWI904084B (zh) | 投遞生物分子至周邊血液單核細胞（ｐｂｍｃ）以調節免疫反應 | |
| US12252545B2 (en) | Therapeutic cell compositions and methods of manufacturing and use thereof | |
| JP2024153792A (ja) | 抗原提示細胞の機能を増強するための生体分子の細胞内送達 | |
| Bevan | Helping the CD8+ T-cell response | |
| JP7046795B2 (ja) | 細孔を有する表面によって媒介される生体分子の細胞内送達 | |
| US20200338125A1 (en) | Method for expansion of lymphocytes | |
| TW202003019A (zh) | 細胞內投遞生物分子以修改免疫反應之方法 | |
| US20230046472A1 (en) | Therapeutic cell compositions and methods of manufacturing and use thereof | |
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| CY1122993T1 (el) | Μεθοδος παραγωγης για πολυδυναμα βλαστοκυτταρα που εχουν αντιγονο-ειδικο γονιδιο υποδοχεα τ κυτταρων | |
| Berk et al. | Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs | |
| KR102426447B1 (ko) | 배아 중간엽 전구 세포를 제조하고 사용하는 방법 | |
| US20210030796A1 (en) | Method for producing antigen-specific t cells | |
| Fontoura et al. | B cells expressing IL-10 mRNA modulate memory T cells after DNA-Hsp65 immunization | |
| AU2018237338A1 (en) | Recombinant | |
| Su et al. | The prospects of human CD40L-activated antigen-presenting B cells |